

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 663 210 A3

(12)

## EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
31.01.1996 Bulletin 1996/05

(51) Int Cl.<sup>6</sup>: A61K 31/445, C07D 491/22

(43) Date of publication A2:  
19.07.1995 Bulletin 1995/29

(21) Application number: 94309771.7

(22) Date of filing: 23.12.1994

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

(30) Priority: 28.12.1993 JP 350037/93

(71) Applicant:  
SUMITOMO PHARMACEUTICALS COMPANY,  
LIMITED  
Osaka 541 (JP)

(72) Inventors:


- Ohashi, Naohito  
Takatsuki-shi (JP)
- Fujiwara, Norio  
Toyonaka-shi (JP)
- Ueda, Yutaka  
Brookline, MA 02156 (US)

(74) Representative:

Cresswell, Thomas Anthony et al  
London WC1R 5LX (GB)


(54) Tumor necrosis factor production inhibitors

(57) Use of a compound of formula (1) or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating a disease caused by a tumor necrosis factor:




(1)

wherein R<sup>1</sup> represents a hydrogen atom, an alkyl group, an alkenyl group, an acyl group or a group of formula:



wherein R<sup>7</sup> represents a halogen atom, a hydroxyl group, an alkoxy group, an alkylthio group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, a cyano group, an amino group, an alkylamino

group, a dialkylamino group, a cycloalkyl group, a heterocyclic group, an aromatic group or an aromatic heterocyclic group; X<sup>1</sup> represents a carbonyl group or a methylene group; and k represents 0 or an integer of 1 to 5, with the proviso that when X<sup>1</sup> is a carbonyl group and R<sup>7</sup> is a hydroxyl group, or when X<sup>1</sup> is a methylene group and R<sup>7</sup> is a hydroxyl group, an amino group, an alkylamino group or a dialkylamino group, k represents an integer of 1 to 5; and, each of A and B independently represents a methylene group or a group of formula:



wherein each of R<sup>2</sup> and R<sup>3</sup> independently represents a hydrogen atom, an alkyl group, an alkoxycarbonyl group or a substituted alkyl group.

EP 0 663 210 A3



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 94 30 9771

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	ACTA UNIV.PALACKI.OLOMUC., FAC.MED., vol. 90, 1979 pages 5-14, 'Isolation and chemistry of alkaloids from plants of the genus papaver. LXXVI' * the whole document *	1-14
A,D	J.PHARM.PHARMACOL., vol. 45, no. 8, August 1993 pages 707-10, 'Ca++-channel blockade in rat thoracic aorta by crychine isolated from Cryptocarya Chinensis Hemsl.' * the whole document *	1-14
A	J.NAT.PROD., vol. 51, no. 4, 1988 pages 760-4, 'Some unusual pavine and isopavine alkaloids from Roemeria refracta' * the whole document *	1-14
A	J.NAT.PROD., vol. 53, no. 5, pages 1267-71, 'Neocaryachine, a new pavine alkaloid from Cryptocarya Chinensis, and NMR spectral properties of related alkaloids' * the whole document *	1-14
The present search report has been drawn up for all claims		
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>17 November 1995</b>
		Examiner <b>Gerli, P</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>A : member of the same patent family, corresponding document</p>		

EPO FORM 150 (04/92) (P0407)